Specifications tableSubject areaCardiology-Atrial fibrillationMore specific subject areaCryoballoon versus radiofrequency ablation impact on platelet and inflammatory biomarkersType of dataAnalyzed tables and individual raw dataHow data was acquiredPlatelet and inflammatory biomarkers were measured from plasma, whole blood, and serum collected at baseline (before procedure), 18--24h and 6-Months postablation in paroxysmal atrial fibrillation patients those who underwent first time cryoballoon and radiofrequency ablation.Data formatRaw and analyzed dataExperimental factorsMeasurement of platelet biomarkers: mean platelet volume (MPV), platelet-leukocyte ratio (P-LCR) and platelet distribution width (PDW) by hematology auto-analyzer (Sysmex XE-2100), P-selectin (CD62P) by flow cytometry (FACSCanto, Becton Dickinson, UK), CD40 ligand (CD40L) and platelet factor-4 (PF-4) by ELISA kits per company instructions (Cloud-Clone Corp).\
Measurement of inflammatory biomarkers: serum high sensitive CRP (hs-CRP) by particle-enhanced immunonephelometry (Cardiophase\* hsCRP, Siemens Healthcare Diagnostics, Germany) and interleukin 6 (IL-6) by latex particle-enhanced immunoassay auto-analyzer (Immulite, Siemens Medical Solutions Diagnostics GmbH, Germany).Experimental featuresProspective, observational randomized cohort to evaluate the short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablationData source locationThe First Affiliated Hospital of Dalian Medical University, Dalian, China.Data accessibilityData available within the articleRelated research articleBin Waleed K, Yin X, Yang X et al. Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation. Int J Cardiol. 2019; 285:128--32 [@bib1] (Published article).\
**Value of the data**•Comparisons of platelet and inflammatory biomarkers after cryoballoon versus radiofrequency ablation in paroxysmal atrial fibrillation patients in both the short- and long-term.•Differences in platelet biomarkers between the two ablation strategies may influence decision-making for AF ablation in the future.•These raw data will be value for future studies while evaluating prothrombotic biomarkers after cryoballoon and radiofrequency ablation in paroxysmal atrial fibrillation.

1. Data {#sec1}
=======

The contents of data are platelet and inflammatory biomarkers values at baseline and 18--24h post-ablation, and at baseline and 6 Months post-ablation between cryoballoon (CB) and radiofrequency (RF) ablation as shown in [Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"} respectively; as well as individual raw data shown in supplementary excel sheet.Table 1Platelet and inflammatory biomarkers at baseline and 18--24h postablation between CB and RF group.Table 1CB (N = 24)RF (N = 26)*P-*value (CB & RF)\
Ba vs. Ba*P-*value (CB & RF)\
18--24h vs. 18--24h*P-*value (CB Group) Ba vs. 18--24h*P-*value (RF Group)\
Ba vs. 18--24hBaseline18--24hBaseline18--24hCD62P (%)18.5 ± 4.429.2 ± 5.817.9 ± 5.934.2 ± 80.654**0.0170.0000.000**CD40L (pg/mL)68 ± 33.8161.6 ± 69.770.3 ± 47.8130.4 ± 62.70.8440.103**0.0000.000**PF-4 (pg/mL)102 ± 23.5130.4 ± 9.2108.5 ± 18.3135.8 ± 11.50.3050.079**0.0000.000**MPV (fL)10.1 ± 0.510.1 ± 0.510.1 ± 0.710.1 ± 0.80.9860.7030.3450.965PDW (fL)11.9 ± 1.111.4 ± 1.111.6 ± 1.611.5 ± 1.50.4200.791**0.025**0.876P-LCR (%)25.9 ± 5.225.5 ± 4.725.7 ± 6.426.4 ± 6.80.8950.5900.5010.350IL-6 (pg/mL)3.3 (1.9--3.9)5.8 (3.1--7.8)3 (1.9--6.7)6.6 (4.4--12.9)0.6170.256**0.0290.014**hs-CRP (mg/L)0.8 (0.5--2)3.7 (1.8--10)0.6 (0.4--2.1)3.3 (2.1--6.2)0.9070.977**0.0000.001**[^1]Table 2Platelet and inflammatory biomarkers at baseline and 6-Months postablation between CB and RF group.Table 2CB (N = 24)RF (N = 26)*P-*value (CB & RF)\
Ba vs. Ba*P-*value (CB & RF)\
6-M vs. 6-M*P-*value (CB Group)\
Ba vs. 6-M*P-*value (RF Group)\
Ba vs. 6-MBaseline6-MBaseline6-MCD62P (%)18.5 ± 4.416.4 ± 3.817.9 ± 5.921.3 ± 6.10.654**0.0020.0210.022**CD40L (pg/mL)68 ± 33.823.8 ± 19.670.3 ± 47.831.6 ± 29.70.8440.285**0.0000.000**PF-4 (pg/mL)102 ± 23.572.7 ± 34.8108.5 ± 18.387 ± 26.50.3050.107**0.0000.000**MPV (fL)10.1 ± 0.59.9 ± 0.510.1 ± 0.710.1 ± 0.70.9860.204**0.010**0.816PDW (fL)11.9 ± 1.111.3 ± 1.111.6 ± 1.611.7 ± 1.30.4200.237**0.004**0.589P-LCR (%)25.9 ± 5.224.3 ± 4.525.7 ± 6.426.2 ± 6.10.8950.209**0.033**0.555IL-6 (pg/mL)3.3 (1.9--3.9)3 (1.9--4.3)3 (1.9--6.7)3.9 (2.1--8.6)0.6170.2300.8460.399hs-CRP (mg/L)0.8 (0.5--2)0.9 (0.6--1.9)0.6 (0.4--2.1)1 (0.5--1.2)0.9070.9610.7750.959[^2]

2. Experimental design, materials and methods {#sec2}
=============================================

The data was collected from 58 symptomatic paroxysmal atrial fibrillation (AF) defined according to expert consensus statement [@bib2] those who undergone first-time CB (n = 29) and RF (n-29) ablation (September 2016--December 2017) at the First Affiliated Hospital of Dalian Medical University as previously described [@bib1], [@bib2], [@bib3], [@bib4].

Peripheral blood samples were collected with a slow withdrawal technique with discarding the first 5 mL at baseline (before procedure), at 18--24 hours (Inpatient stay) and 6-Months postablation during outpatient follow-up. The mean platelet volume (MPV), platelet-leukocyte ratio (P-LCR) and platelet distribution width (PDW) were measured within 30 minutes from complete blood count analysis by hematology auto-analyzer (Sysmex XE-2100). The platelet surface expression of P-selectin (CD62P) was measured from citrate blood sample within 4 hours by flow cytometry (FACSCanto, Becton Dickinson, UK) as described previously [@bib5]. The ELISA Kits were used to measure CD40 ligand (CD40L) and platelet factor-4 (PF-4) per company instructions (Cloud-Clone Corp). Serum high sensitive CRP (hs-CRP) by particle-enhanced immunonephelometry (Cardiophase\* hsCRP, Siemens Healthcare Diagnostics, Germany) and interleukin 6 (IL-6) by latex particle-enhanced immunoassay auto-analyzer (Immulite, Siemens Medical Solutions Diagnostics GmbH, Germany) were measured within 30 minutes.

SPSS 23 (IBM) was used for all statistical analyses with a p-value ≤ 0.05 considered as statistically significant. Comparison of biomarkers between CB and RF groups was performed using the independent *t*-test or Mann-Whitney-U test at baseline, 18--24h and 6-Months postablation as appropriate. The paired *t*-test or Wilcoxon signed rank test was used for repeated measurements from baseline to 18--24h or 6-Months postablation in both groups.
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[^1]: Data are expressed as mean ± SD, median or interquartile range (25th-75th percentile), bold letters are significant and unless otherwise stated. Ba = Baseline, CB = cryoballoon, CD40L = CD40 ligand, CD62P = P-selectin, h = hour, hs-CRP = high sensitive CRP, IL-6 = interleukin 6, MPV = mean platelet volume, N = number, PF-4 = platelet factor-4, PDW = platelet distribution width, P-LCR = platelet-leukocyte ratio, and RF = radiofrequency.

[^2]: Data are expressed as mean ± SD, median or interquartile range (25th-75th percentile), bold letters are significant and unless otherwise stated. Ba = Baseline, CB = cryoballoon, CD40L = CD40 ligand, CD62P = P-selectin, hs-CRP = high sensitive CRP, IL-6 = interleukin 6, MPV = mean platelet volume, N = number, PF-4 = platelet factor-4, PDW = platelet distribution width, P-LCR = platelet-leukocyte ratio, RF = radiofrequency, and 6-M = 6-Months postablation.
